GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cardiovascular Systems Inc (NAS:CSII) » Definitions » Altman Z2-Score

Cardiovascular Systems (Cardiovascular Systems) Altman Z2-Score : 1.97 (As of May. 06, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Cardiovascular Systems Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Cardiovascular Systems has a Altman Z2-Score of 1.97, indicating it is in Grey Zones. This implies that Cardiovascular Systems is in some kind of financial stress. If it is below 1.1, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Cardiovascular Systems's Altman Z2-Score or its related term are showing as below:

CSII' s Altman Z2-Score Range Over the Past 10 Years
Min: -8.12   Med: 0.9   Max: 21.08
Current: 1.97

During the past 13 years, Cardiovascular Systems's highest Altman Z2-Score was 21.08. The lowest was -8.12. And the median was 0.90.


Cardiovascular Systems Altman Z2-Score Historical Data

The historical data trend for Cardiovascular Systems's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiovascular Systems Altman Z2-Score Chart

Cardiovascular Systems Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.11 1.47 4.71 4.02 2.67

Cardiovascular Systems Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.63 3.00 2.67 2.36 1.97

Competitive Comparison of Cardiovascular Systems's Altman Z2-Score

For the Medical Devices subindustry, Cardiovascular Systems's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiovascular Systems's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cardiovascular Systems's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Cardiovascular Systems's Altman Z2-Score falls into.



Cardiovascular Systems Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Cardiovascular Systems's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.5945+3.26*-1.4234+6.72*-0.1159+1.05*3.3195
=1.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2022:
Total Assets was $311.5 Mil.
Total Current Assets was $222.0 Mil.
Total Current Liabilities was $36.8 Mil.
Retained Earnings was $-443.4 Mil.
Pre-Tax Income was -7.839 + -10.65 + -9.642 + -9.595 = $-37.7 Mil.
Interest Expense was -0.404 + -0.406 + -0.407 + -0.408 = $-1.6 Mil.
Total Liabilities was $72.1 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(221.96 - 36.761)/311.506
=0.5945

X2=Retained Earnings/Total Assets
=-443.413/311.506
=-1.4234

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-37.726 - -1.625)/311.506
=-0.1159

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(239.389 - 0)/72.117
=3.3195

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Cardiovascular Systems has a Altman Z2-Score of 1.97 indicating it is in Grey Zones.


Cardiovascular Systems  (NAS:CSII) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Cardiovascular Systems Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Cardiovascular Systems's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiovascular Systems (Cardiovascular Systems) Business Description

Traded in Other Exchanges
N/A
Address
1225 Old Highway 8 Northwest, Saint Paul, MN, USA, 55112-6416
Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generate the vast majority of its revenue in the United States.
Executives
Jeffrey S. Points officer: Chief Financial Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Scott R Ward director RAYMOND HOLDINGS, LLC, 6410 BALLANTINE CT., INVER GROVE HEIGHTS MN 55077
Erik Paulsen director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Rhonda J. Robb officer: Chief Operating Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Martha Goldberg Aronson director 40 WEST HIGHLAND PARK DRIVE NE, HUTCHINSON MN 55350
Sachin H. Jain director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Alexander Rosenstein officer: General Counsel & Corp. Secy C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Sandra Sedo officer: Chief Compliance Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Kelvin K. Womack director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen J. Rempe officer: Chief Human Resources Officer C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
John M. Hastings officer: VP Manufacturing & Operations C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen Stenbeck director C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Ryan Egeland officer: VP of Medical Affairs C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
David Whitescarver officer: VP of Corp. Dev. & IP C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Laura Gillund officer: Chief Talent Officer